18 completed, 13 recruiting, 10 unknown, 9 active not recruiting. 17 Not applicable, 12 Phase 2, 8 Phase 1, 2 Phase 3, 1 Phase 4.
Follow BRCA2 Mutation: new trials by email Literature Review of BRCA2 Mutation trials Research Report on BRCA2 Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer Exemestane, Tamoxifen - Breast Cancer, Ductal Carcinoma | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 140 | 2026-09-09 | 2026-03-30 |
| Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene Cognitive-behavioral group therapy - Breast Cancer Susceptibility Gene (BRCA1) Mutation, BRCA2 Mutation | Not applicable | Recruiting | CHU de Quebec-Universite Laval | 250 | 2026-02-01 | 2026-03-31 |
| Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy Experimental Arm, SOC Arm - BRCA1 Mutation, BRCA2 Mutation | Not applicable | Recruiting | Duke University | 50 | 2025-09-30 | 2026-08-04 |
| BRCA Mutation Carriers' Platform a Multicenter Study Registration of clinical datas in the platform - BRCA1 Mutation, BRCA2 Mutation | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 10000 | 2025-04-05 | 2025-11-28 | |
| Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer Olaparib + Elacestrant, Olaparib - Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced or Metastatic Breast Cancer | Phase 2 | Recruiting | GBG Forschungs GmbH | 176 | 2024-12-13 | 2025-12-01 |
| Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer Axatilimab, Olaparib - Breast Cancer, PALB2-Mutated Breast Carcinoma | Phase 1 | Recruiting | Dana-Farber Cancer Institute | 20 | 2024-08-13 | 2026-09-02 |
| Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer Pembrolizumab, Paclitaxel, Carboplatin - Triple Negative Breast Neoplasms, Triple Negative Breast Cancer | Phase 2 | Recruiting | Okayama University | 23 | 2024-07-16 | 2025-03-20 |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies ETX-19477 - Advanced or Metastatic Solid Tumors, Breast Cancer | Phase 1 / Phase 2 | Recruiting | 858 Therapeutics, Inc. | 120 | 2024-05-13 | 2026-03-27 |
| Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors ACE-86225106 tablet - Solid Tumor, Adult, BRCA1 Mutation | Phase 1 / Phase 2 | Active not recruiting | Acerand Therapeutics (Shanghai) Limited | 298 | 2024-03-22 | 2026-08-04 |
| Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors Olaparib, ASTX727 - BRCA1 Mutation, BRCA2 Mutation | Phase 1 | Active not recruiting | Varun Monga, MBBS | 13 | 2024-02-07 | 2026-10-20 |
| Chemo-free BRCA-targeted Neoadjuvant Strategy olaparib, Durvalumab - TNBC - Triple-Negative Breast Cancer, BRCA1 Mutation | Phase 2 | Withdrawn | European Organisation for Research and Treatment of Cancer - EORTC | 2024-02-01 | 2024-02-23 | |
| Contribution of Oncogenetics in Breast Cancer in Reunion Epidemiology of Breast Cancer in Reunion: Study of the Reunion Mutation on BRCA2 blood sample for BRCA2 mutation detection - Breast Cancer, Genetic Disease | Not applicable | Completed | Centre Hospitalier Universitaire de la Réunion | 228 | 2023-10-19 | 2026-09-16 |
| Combination Therapy in Cancers With Mutations in DNA Repair Genes Niraparib, Irinotecan - Metastatic Solid Tumor, BRCA1 Mutation | Phase 1 | Recruiting | University of California, San Francisco | 24 | 2023-05-23 | 2026-06-18 |
| Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations Olaparib, LHRH agonist - Prostate Cancer, BRCA1 Mutation | Phase 2 | Active not recruiting | Rana McKay, MD | 32 | 2023-02-01 | 2026-07-10 |
| An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results Intervention Arm At-risk Relative/ARR Contacts, MyGene Portal, Standard of Care - BRCA1 Mutation, POLD1 Gene Mutation | Not applicable | Recruiting | Memorial Sloan Kettering Cancer Center | 1000 | 2022-12-01 | 2026-08-27 |
| Pilot Study of Single-port Robot-assisted Nipple-sparing Mastectomy da Vinci SPⓇ Single-port System - Nipple-sparing Mastectomy, Prophylactic Mastectomy | Not applicable | Unknown | Chang Gung Memorial Hospital | 30 | 2022-07-30 | 2023-04-25 |
| LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients Illumina panel - Lobular Breast Carcinoma, Lobular in Situ Breast Carcinoma | Active not recruiting | European Institute of Oncology | 800 | 2022-05-16 | 2025-12-04 | |
| Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma Ovarian Cancer, High Grade Serous Carcinoma | Unknown | Liz-Anne Lewsley | 250 | 2021-10-27 | 2022-09-23 | |
| FaCT Trial (Facilitated Cascade Testing Trial) Family Letter (Standard of Care), Educational Video, Mailed Saliva Kit for Genetic Testing - BRCA1 Mutation, BRCA2 Mutation | Not applicable | Active not recruiting | Weill Medical College of Cornell University | 524 | 2021-07-21 | 2026-06-30 |
| Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening liquid biopsy - Breast Cancer Female, BRCA1 Mutation | Not applicable | Active not recruiting | Centre Jean Perrin | 1100 | 2021-05-31 | 2025-09-10 |
Showing 20 of 58. Sign in to see all of them.
Breast Neoplasms (28) · Ovarian Neoplasms (12) · Prostatic Neoplasms (6) · Carcinoma, Ovarian Epithelial (5) · Neoplasms (5) · Colorectal Neoplasms, Hereditary Nonpolyposis (3) · Fallopian Tube Neoplasms (3) · Neoplasm Metastasis (3) · Adnexal Diseases (2) · Breast Diseases (2) · Carcinoma (2) · Fanconi Anemia, Complementation Group D1 (2) · Genetic Predisposition to Disease (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2)
Neoplasms (39) · Neoplasms by Site (39) · Skin Diseases (32) · Skin and Connective Tissue Diseases (32) · Breast Diseases (29) · Genital Diseases (19) · Urogenital Diseases (19) · Endocrine System Diseases (17) · Endocrine Gland Neoplasms (16) · Female Urogenital Diseases (16) · Female Urogenital Diseases and Pregnancy Complications (16) · Urogenital Neoplasms (16) · Gonadal Disorders (15) · Adnexal Diseases (14) · Genital Diseases, Female (14)
olaparib (9) · Standard of Care (3) · Blood Specimen Collection (2) · Carboplatin (2) · niraparib (2) · Absorptiometry, Photon (1) · Ascorbic Acid (1) · Bevacizumab (1) · Biopsy (1) · Botulinum Toxins, Type A (1) · Carmustine (1) · Chorionic Gonadotropin (1) · Diet Therapy (1) · Fulvestrant (1) · Genetic Profile (1)
Abramson Cancer Center at Penn Medicine (2) · Dana-Farber Cancer Institute (2) · European Institute of Oncology (2) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (2) · Georgetown University (2) · Lei Li (2) · Massachusetts General Hospital (2) · Memorial Sloan Kettering Cancer Center (2) · University Health Network, Toronto (2) · Weill Medical College of Cornell University (2) · Xiaoxiang Chen (2) · 858 Therapeutics, Inc. (1) · Acerand Therapeutics (Shanghai) Limited (1) · Associazione Italiana per lo Studio del Pancreas (1) · Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo (1)
United States (25) · Italy (7) · China (5) · France (5) · Canada (3) · Netherlands (2) · South Korea (2) · United Kingdom (2) · Belgium (1) · Germany (1) · Japan (1) · Russia (1) · Taiwan (1)
Kenneth Offit, MD, MPH (2) · Varun Monga, MBBS (2) · Xiaoxiang Chen, MD,PhD (2) · Alessandra Fabi (1) · Anna Fagotti (1) · Antonio Toesca, MD (1) · Arnold Glazier, M.D. (1) · Daniel McCormick (1) · Deborah Farr, M.D. (1) · Derek Yang, MD (1) · Don S Dizon, MD (1) · Etienne Brain (1) · Filipa Lynce, MD (1) · Flora E van Leeuwen, Phd (1)
PMID 24606898, PMID 26094889, PMID 30103738, PMID 30538291, PMID 32807084, PMID 33357965, PMID 33443030, PMID 33480862, PMID 34173196, PMID 34449252, PMID 35235412, PMID 35395021, PMID 35583693, PMID 35705312, PMID 35849397, PMID 36403862, PMID 36670100, PMID 36710203, PMID 36831483, PMID 37027812, PMID 37775701, PMID 37787643, PMID 37972346, PMID 38453598, PMID 39173603, PMID 40262388, PMID 40632977, PMID 41045325, PMID 41724092
2015 (1), R01CA255613 (1)